NCT03832452 - A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions

Healthy

Interventions

DRUG

Lucerastat (Treatment A)

2000 and 4000 mg; hard capsules for oral administration

OTHER

Placebo

hard capsules for oral administration

DRUG

Moxifloxacin

400 mg; film-coated tablets for oral administration

DRUG

Lucerastat (Treatment B)

1000 mg; hard capsules for oral administration

DRUG

Lucerastat (Treatment C)

4000 mg; hard capsules for oral administration

Trial Locations (1)

QPS Netherlands B.V., Groningen